Feature | October 31, 2013

Boston Scientific Receives CE Mark for Lotus Valve System

TAVR device offers precise positioning and placement, offering physicians unprecedented control

heart valve repair hybrid or cath lab
October 31, 2013 — Boston Scientific Corp. has received CE mark for its Lotus Valve System, a transcatheter aortic valve replacement (TAVR) technology. This key approval offers an effective new treatment alternative for patients with severe aortic stenosis at high risk with surgical valve replacement.
 
The Lotus Valve System is immediately available to select centers in Europe, with commercial site expansion accelerating as physicians and centers become fully trained. It is designed to provide physicians increased control during implantation and to help provide a more precise, predictable procedure. It is the only aortic valve device that can be assessed in its final position prior to release while maintaining the ability for the physician to reposition or fully resheath and retrieve the valve. The Lotus Valve System also incorporates Adaptive Seal technology designed to minimize aortic regurgitation.
 
"The ability to initially position the Lotus Valve precisely and, if needed, to easily reposition or fully retrieve the valve provides the operator with remarkable control," said Ian Meredith, director of MonashHeart at Monash Medical Centre, Melbourne, Australia and principal investigator, REPRISE II trial. "Combined with early and often complete elimination of aortic regurgitation as observed in REPRISE II, the unique features of the Lotus Valve technology represent a significant step forward in the percutaneous treatment of eligible patients with severe symptomatic aortic stenosis."
 
Data presented at the PCR London Valves course in September demonstrated the Lotus Valve System met the primary performance endpoint for the first 60-patient cohort and was implanted successfully in all patients with no cases of severe paravalvular regurgitation. In 76.1 percent of patients, there was no corelab adjudicated paravalvular regurgitation at six months.
 
"Results from the REPRISE II trial highlight the promise behind the Lotus Valve System, especially related to avoiding moderate or severe paravalvular leaks," said Nicolas Van Mieghem, M.D., Erasmus Medical Center, Rotterdam, Netherlands. "In addition to providing a new treatment option for TAVR, the Lotus Valve has the potential to improve clinical outcomes by minimizing paravalvular leaks."
 
The Lotus Valve System comes pre-loaded on a transfemoral delivery system, which is inserted through a small incision in the leg. Available in a 23 mm and 27 mm size, the Lotus Valve System can treat patients with aortic annulus sizes from 20 mm to 27 mm. The Lotus Valve System is an investigational device in the United States and Japan, and is not available for sale in those countries.
 
For more information: www.bostonscientific.com

Related Content

The Edwards Konect Resilia aortic valved conduit (AVC).
News | Heart Valve Technology | July 15, 2020
July 15, 2020 —  The U.S. Food and Drug Administration (FDA) granted clearance for the Edwards Lifesciences Corp.
The Foldax Tria surgical valve reimagines the heart valve by incorporating a new, proprietary biopolymer, what the vendor calls LifePolymer, with an innovative valve design intended to eliminate calcification, withstand stresses and strains without failure, and restore patient quality of life without lifelong use of anticoagulants. Tria is also the first heart valve to be robotically manufactured, reducing variability, enabling high precision, repeatability and better quality control.
News | Heart Valve Technology | June 23, 2020
June 23, 2020 – Heart valve start-up Foldax is looking to reinventi
SMT Enters Structural Heart Market With Acquisition of Vascular Concepts. The company's Hydra TAVR (TAVI) valve gained European CE mark clearance in June 2020.
News | Heart Valve Technology | June 19, 2020
June 19, 2020 — SMT (Sahajanand Medical Technologies Pvt.
SMT (Sahajanand Medical Technology Private Ltd.), a leading medical device company of India focused on cardiology, announced it Hydra transcatheter aortic valve replacement (TAVR) device received European CE mark approval. It is indicated for the treatment of patients diagnosed with aortic stenosis. #SMT #HYDRA #TAVR

The self-expanding SMT Hydra transcatheter aortic valve replacement (TAVR) device.

Feature | Heart Valve Technology | June 09, 2020
June 9, 2020 — SMT (Sahajanand Medical Technology Private Ltd.), a leading medical device company in India focused on
News | Heart Valve Technology | June 08, 2020
June 8, 2020 — Edwards Lifesciences Corp.
Edwards Lifesciences Pascal Tricuspid Valve Transcatheter Repair System Approved in Europe
News | Heart Valve Technology | May 18, 2020
May 18, 2020 — The Edwards Lifesciences Corp.
Key TAVR Takeaways From ACC 2020
Feature | Heart Valve Technology | April 20, 2020 | Dave Fornell, Editor
Some U.S.
Abbott announced its TriClip Transcatheter Tricuspid Valve Repair (TTVR) System has received European CE mark clearance as a non-surgical treatment for people with a tricuspid valve regurgitation (TR). 
Feature | Heart Valve Technology | April 09, 2020
April 9, 2020 — Abbott announced its TriClip Transcatheter Tricuspid Valve Repair (TTVR) System has received European
The Edwards Lifesciences Cardioband for tricuspid valve regurgitation. #COVID19 #coronavirus

The Edwards Lifesciences Cardioband for tricuspid valve regurgitation is one of the device trials being paused for the duration of the COVID-19 outbreak.

News | Heart Valve Technology | March 30, 2020
March 30, 2020 — Edwards Lifesciences Corp.